Clinilabs is excited to join our first Xtalks webinar!
This webinar explores how specialty CROs deliver strategic value across drug and device development—from deep therapeutic expertise to agile operations and stronger sponsor collaboration.
Hear insights from experts in capital markets, specialty CROs, and pharma/biotech as they discuss the evolving role of CROs in today’s clinical landscape.
Webinar details:
- Date: Friday, October 17, 2025
- Time: 12 pm EDT (5 pm BST/UK)
To read the full press release, visit: The Value Proposition of Specialty CROs
Presenters:
Gary Zammit, PhD, Founder, President, CEO, Clinilabs. He established the company in 2000 to advance CNS drug and device development. A recognized expert in neuropsychiatric drug development and sleep medicine, he is also a Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. Dr. Zammit has authored over 250 publications and two books, with a third due in Fall 2025. His leadership continues to drive innovation and excellence in psychiatric and neurological therapeutics.
Colin Orford, PhD, Therapeutic Lead, Psychiatry, Clinilabs. He is a veteran drug development executive with 33+ years of experience at GSK, Novartis, Quintiles, Eisai and ICON. He has led R&D projects from preclinical through Phase IIIb, with deep expertise in neuroscience, including depression, anxiety, Alzheimer’s and sleep disorders. Colin also brings 10 years of biotech consulting experience, strong regulatory knowledge (US, EU and Japan) and a proven track record in due diligence, clinical strategy and adaptive trial design. He previously founded and led ICON’s drug development consulting team.
Mehran Ahmed, Partner, InTandem Capital Partners. He has over 20 years of experience in private equity and finance, with a specialization in middle-market growth strategies. He brings deep healthcare expertise, having led and advised companies across pharmaceutical services, clinical trials, life sciences, behavioral health and more. Before InTandem, Mehran was a Managing Director at Webster Equity Partners and held roles at Gemini Investors, Arsenal Capital Partners and Morgan Stanley. He has a BA from Bowdoin College, where he was a Sarah and James Bowdoin scholar.
Michael J. Detke, MD, PhD, Founder, Detke Biopharma Consulting LLC, Clinical Professor, Psychiatry, Indiana University. He is a board-certified Psychiatrist and CNS drug development expert with over 25 years of experience in biotech and pharma. He has led clinical programs across all phases, including INDs and NDAs, and held CMO roles at Lighthouse, Cortexyme, Embera, CoMentis and MedAvante. At Eli Lilly, he oversaw global development for Cymbalta and Prozac. Dr. Detke is the founder of Detke Biopharma Consulting LLC, which advises pharma, biotech and NIH on CNS strategy and regulatory affairs. He is a Clinical Professor of Psychiatry at Indiana University and has published over 70 peer-reviewed papers.
